IOTECH in times of COVID-19 by J. Haanen

Get full text

Relatieve prestatiemeting bij AEX-fondsen by R. A. J. Haanen, V. S. Maas, S. P. Van Triest

Get full text

Variations in the exposure to sunitinib with immediate and deferred cytoreductive nephrectomy (CN). A post-hoc analysis of the randomized controlled EORTC SURTIME trial by Y. Abu-Ghanem, H. Van Thienen, C. Blank, T. Powles, L. Collette, B. Tombal, J. Haanen, A. Bex

Get full text

De totstandkoming van de introductieprijs bij IPO’S by M. J. Van Den Assem, R. A. J. Haanen, R. E. Krol, G. J. A. M. Van Logtestijn, N. L. Van Der Sar

Get full text

Real-World data of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place by A. Bex, N. Graafland, A. Meerveld-Eggink, S. Wilgenhof, J. Van Thienen, F. Lalezari, M. Grant, B. Szabados, Y. Abu-Ghanem, T. Kuusk, E. Boleti, C. Blank, T. Powles, J. Haanen

Get full text

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit by I. Johanna, A. Daudeij, F. Devina, C. Nijenhuis, B. Nuijen, B. Romberg, C. de Haar, J. Haanen, H. Dolstra, E. Bremer, Z. Sebestyen, T. Straetemans, I. Jedema, J. Kuball

Get full text